+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acquired von Willebrand Disease (AvWD) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • PDF Icon

    Report

  • 138 Pages
  • August 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5632154
Description Jump to:
Acquired von Willebrand syndrome is a highly heterogeneous bleeding disorder, usually displays mild to moderate hemorrhagic symptoms that may at times be severe too. Many a time the severity increases post-surgery. AvWS is considered as a rare disorder, however, the actual prevalence is not as rare. In case the laboratory findings diagnoses vWD in a patient with no family history, AvWD associated conditions is usually explored. The acquired von willebrand disease treatment market is anticipated to grow, at a CAGR of 5.86% during the forecast period of 2022 to 2030.

Diagnosis Remains as The Largest Challenge

AvWD screening becomes crucial in patients with onco-hematologic disorders, patients who experienced unexplained bleeding, or before undergoing any invasive procedure. The acquired von Willebrand disease prevalence represents about 1% to 5% of all von Willebrand disease. Its prevalence is higher in certain groups. For example, it has been reported up to 20% of malignancies, and up to 100% of certain high flow states such as extracorporeal membrane oxygenation (ECMO) and metallic cardiac valves. The diagnostic complexity and milder form of AvWS without symptoms make it difficult to finalize on the actual prevalence rate of AvWD.

Increasing Support of Governments Led by Increasing Awareness of AvWS

The demand for the AvWD treatment market has increased as governments across the globe have become increasingly aware of the von Willebrand syndrome and its associated treatment. The treatment for this condition varies across countries. Hpwever, one of the significant driver impacting the market revenues is rising prevalence of bleeding disorders especially acquired bleeding disorders. Von Willebrand disease is a fairly prevalent bleeding disorder, according to the World Federation of Hemophilia. Von Willebrand disease is caused by a deficiency in the protein known as the Von Willebrand factor, which is present in the blood.

Desmopressin records the highest revenues

In the year 2021, Desmopressin recorded the highest revenues in comparison to the other drugs. Desmopressin remains as the first line therapy for AvWD and is proven to be efficient for patients with mild symptoms. Easy accessibility of Desmopressin across the globe and availability of Desmopressin through different routes of drug administration such as injection, tablet and intranasal spray remains as the key driver for the dominance of this market segment.

Injections Remained as Dominant Form Among Route of Drug Administration

In the year 2021, Injection as a mode of AvWD drug administration dominated the market segment with revenues of about $ 20,880 thousand. Major AvWD treatment drugs are administered through injections and infusions. Primary drug Desmopressin is widely administered through injections, similarly replacement therapies are also administered through this route. Injections respond very quickly during emergency and are very effective mode of drug administration. Therefore, the market is also expected to grow at the fastest pace during the forecast period.

North America Dominates In terms of Market Revenues

North America was observed as the largest market for AvWD treatment in 2021. North America dominated the market due to its aging population, supportive government policies, high awareness associated with hemophilia and types in people, and developed healthcare infrastructure. Asia Pacific was observed as the attractive market for AvWS treatment due to its emerging healthcare infrastructure, high disposable income, transforming government policies specific to orphan diseases diagnosis and treatment, and rising public awareness associated with healthcare insurance and disease diagnosis. The key players in the acquired AvWS treatment market are Novo Nordisk A/S, Genentech, Inc., F. Hoffman-La Roche AG, Sanofi SA, and others.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. Key data points that enables the estimation of Acquired von Willebrand Disease (AvWD) Treatment market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Acquired von Willebrand Disease (AvWD) Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Acquired von Willebrand Disease (AvWD) Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Acquired von Willebrand Disease (AvWD) Treatment market?
  • Which is the largest regional market for Acquired von Willebrand Disease (AvWD) Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Acquired von Willebrand Disease (AvWD) Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Acquired von Willebrand Disease (AvWD) Treatment market worldwide?


This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Acquired von Willebrand Disease (AvWD) Treatment Market
2.2. Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Treatment Type, 2021 (US$ Million)
2.3. Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Replacement Therapy, 2021 (US$ Million)
2.4. Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Route of Drug Administration, 2021 (US$ Million)
2.5. Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Healthcare Settings, 2021 (US$ Million)
2.6. Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Geography, 2021 (US$ Million)
2.7. Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Impact of COVID-19, 2020 (US$ Million)
2.8. Key Investment Proposition by Geography, 2021
2.9. Competitive Analysis
2.10. Key Industry Strategies
2.11. Tier Analysis 2021 Versus 2030
2.12. Key Buying Criteria
2.13. Key Case Reports
2.14. Scenario Analysis
2.15. Optimistic estimates and analysis
2.16. Realistic estimates and analysis
2.17. Pessimistic estimates and analysis
2.18. Market Profiling
2.19. Sales and Marketing Plan
2.20. Heptalysis Analysis
2.21. Critical Investigation of Business Problems Through Five Whys Root Cause Analysis & Relevant Solutions
2.22. Top Market Conclusions
2.23. Strategic Recommendations
3. Acquired von Willebrand Disease (AvWD) Treatment Market: Business Outlook & Market Dynamics
3.1. Introduction
3.2. Global Acquired von Willebrand Disease (AvWD) Treatment Market Value, 2020-2030, (US$ Million)
3.3. Key Trends Analysis
3.4. Market Dynamics
3.4.1. Market Drivers
3.4.2. Market Restraints
3.4.3. Key Challenges
3.4.4. Key Opportunities
3.5. Impact Analysis of Drivers and Restraints
3.6. See-Saw Analysis
3.7. Attractive Investment Proposition
3.8. Porter’s Five Force Model
3.8.1. Supplier Power
3.8.2. Buyer Power
3.8.3. Threat Of Substitutes
3.8.4. Threat Of New Entrants
3.8.5. Competitive Rivalry
3.9. PESTEL Analysis
3.9.1. Political Landscape
3.9.2. Economic Landscape
3.9.3. Technology Landscape
3.9.4. Legal Landscape
3.9.5. Social Landscape
3.10. Competitive Landscape
3.10.1. Market Positioning of Key Acquired von Willebrand Disease (AvWD) Treatment Market Vendors
3.10.2. Strategies Adopted by Acquired von Willebrand Disease (AvWD) Treatment Market Vendors
4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
4.1. Market Overview
4.2. Growth & Revenue Analysis: 2021 Versus 2030
4.3. Market Segmentation
4.3.1. Desmopressin
5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Clot-stabilizing Medications/anti-fibrinolytic medications
5.3.2. Others
6. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. Oral
6.3.2. Injection
6.3.3. Others
7. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2021 Versus 2030
7.3. Market Segmentation
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Others
8. North America Acquired von Willebrand Disease (AvWD) Treatment Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
8.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
8.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
8.5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
8.6.Acquired von Willebrand Disease (AvWD) Treatment Market: By Region, 2020-2030, USD (Million)
8.6.1.North America
8.6.1.1. U.S.
8.6.1.1.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
8.6.1.1.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
8.6.1.1.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
8.6.1.1.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
8.6.1.2. Canada
8.6.1.2.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
8.6.1.2.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
8.6.1.2.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
8.6.1.2.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
8.6.1.3. Rest of North America
8.6.1.3.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
8.6.1.3.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
8.6.1.3.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
8.6.1.3.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
9. UK and European Union Acquired von Willebrand Disease (AvWD) Treatment Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
9.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
9.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
9.5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
9.6.Acquired von Willebrand Disease (AvWD) Treatment Market: By Region, 2020-2030, USD (Million)
9.6.1.UK and European Union
9.6.1.1. UK
9.6.1.1.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
9.6.1.1.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
9.6.1.1.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
9.6.1.1.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
9.6.1.2. Germany
9.6.1.2.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
9.6.1.2.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
9.6.1.2.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
9.6.1.2.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
9.6.1.3. Spain
9.6.1.3.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
9.6.1.3.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
9.6.1.3.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
9.6.1.3.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
9.6.1.4. Italy
9.6.1.4.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
9.6.1.4.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
9.6.1.4.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
9.6.1.4.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
9.6.1.5. France
9.6.1.5.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
9.6.1.5.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
9.6.1.5.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
9.6.1.5.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
9.6.1.6. Rest of Europe
9.6.1.6.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
9.6.1.6.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
9.6.1.6.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
9.6.1.6.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
10. Asia Pacific Acquired von Willebrand Disease (AvWD) Treatment Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
10.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
10.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
10.5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
10.6.Acquired von Willebrand Disease (AvWD) Treatment Market: By Region, 2020-2030, USD (Million)
10.6.1.Asia Pacific
10.6.1.1. China
10.6.1.1.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
10.6.1.1.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
10.6.1.1.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
10.6.1.1.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
10.6.1.2. Japan
10.6.1.2.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
10.6.1.2.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
10.6.1.2.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
10.6.1.2.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
10.6.1.3. India
10.6.1.3.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
10.6.1.3.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
10.6.1.3.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
10.6.1.3.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
10.6.1.4. Australia
10.6.1.4.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
10.6.1.4.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
10.6.1.4.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
10.6.1.4.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
10.6.1.5. South Korea
10.6.1.5.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
10.6.1.5.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
10.6.1.5.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
10.6.1.5.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
10.6.1.6. Rest of Asia Pacific
10.6.1.6.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
10.6.1.6.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
10.6.1.6.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
10.6.1.6.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
11. Latin America Acquired von Willebrand Disease (AvWD) Treatment Market, 2020-2030, USD (Million)
11.1. Market Overview
11.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
11.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
11.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
11.5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
11.6.Acquired von Willebrand Disease (AvWD) Treatment Market: By Region, 2020-2030, USD (Million)
11.6.1.Latin America
11.6.1.1. Brazil
11.6.1.1.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
11.6.1.1.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
11.6.1.1.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
11.6.1.1.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
11.6.1.2. Mexico
11.6.1.2.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
11.6.1.2.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
11.6.1.2.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
11.6.1.2.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
11.6.1.3. Rest of Latin America
11.6.1.3.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
11.6.1.3.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
11.6.1.3.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
11.6.1.3.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
12. Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market, 2020-2030, USD (Million)
12.1. Market Overview
12.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
12.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
12.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
12.5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
12.6.Acquired von Willebrand Disease (AvWD) Treatment Market: By Region, 2020-2030, USD (Million)
12.6.1.Middle East and Africa
12.6.1.1. GCC
12.6.1.1.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
12.6.1.1.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
12.6.1.1.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
12.6.1.1.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
12.6.1.2. Africa
12.6.1.2.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
12.6.1.2.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
12.6.1.2.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
12.6.1.2.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
12.6.1.3. Rest of Middle East and Africa
12.6.1.3.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
12.6.1.3.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
12.6.1.3.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
12.6.1.3.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
13. Company Profile
13.1. Baxter Healthcare Corporation
13.1.1. Company Overview
13.1.2. Financial Performance
13.1.3. Product Portfolio
13.1.4. Strategic Initiatives
13.2. Biogen
13.2.1. Company Overview
13.2.2. Financial Performance
13.2.3. Product Portfolio
13.2.4. Strategic Initiatives
13.3. Pfizer
13.3.1. Company Overview
13.3.2. Financial Performance
13.3.3. Product Portfolio
13.3.4. Strategic Initiatives
13.4. F. HOFFMAN LA ROCHE
13.4.1. Company Overview
13.4.2. Financial Performance
13.4.3. Product Portfolio
13.4.4. Strategic Initiatives
13.5. Sanofi
13.5.1. Company Overview
13.5.2. Financial Performance
13.5.3. Product Portfolio
13.5.4. Strategic Initiatives
13.6. Ferring Pharmaceuticals
13.6.1. Company Overview
13.6.2. Financial Performance
13.6.3. Product Portfolio
13.6.4. Strategic Initiatives
13.7. Genentech, Inc.
13.7.1. Company Overview
13.7.2. Financial Performance
13.7.3. Product Portfolio
13.7.4. Strategic Initiatives
13.8. Bristol Myers Squibb
13.8.1. Company Overview
13.8.2. Financial Performance
13.8.3. Product Portfolio
13.8.4. Strategic Initiatives
13.9. Novo Nordisk
13.9.1. Company Overview
13.9.2. Financial Performance
13.9.3. Product Portfolio
13.9.4. Strategic Initiatives
13.10. GlaxoSmithKline plc
13.10.1. Company Overview
13.10.2. Financial Performance
13.10.3. Product Portfolio
13.10.4. Strategic Initiatives
13.11. Takeda Pharmaceutical
13.11.1. Company Overview
13.11.2. Financial Performance
13.11.3. Product Portfolio
13.11.4. Strategic Initiatives
13.12. CSL Behring
13.12.1. Company Overview
13.12.2. Financial Performance
13.12.3. Product Portfolio
13.12.4. Strategic Initiatives
13.13. Bayer AG
13.13.1. Company Overview
13.13.2. Financial Performance
13.13.3. Product Portfolio
13.13.4. Strategic Initiatives
List of Figures
Figure 1 Global Acquired von Willebrand Disease (AvWD) Treatment Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Acquired von Willebrand Disease (AvWD) Treatment Market: Quality Assurance
Figure 5 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Treatment Type, 2021
Figure 6 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Replacement Therapy, 2021
Figure 7 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Route of Drug Administration, 2021
Figure 8 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Healthcare Settings, 2021
Figure 9 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Geography, 2021
Figure 10 Market Geographical Opportunity Matrix - Global Acquired von Willebrand Disease (AvWD) Treatment Market, 2021
Figure 11 Market Positioning of Key Acquired von Willebrand Disease (AvWD) Treatment Market Players, 2021
Figure 12 Global Acquired von Willebrand Disease (AvWD) Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 13 Porters Five Force Model - Current, Midterm and Long Term Perspective
Figure 14 See Saw Analysis
Figure 15 PETEL Analysis
Figure 16 Key Buying Criteria: Current and Long-Term Perspective
Figure 17 Global Acquired von Willebrand Disease (AvWD) Treatment Market, Scenario Analysis, 2020 to 2030 (US$ Million)
Figure 18 Heptalysis Analysis: Global Acquired von Willebrand Disease (AvWD) Treatment Market
Figure 19 Five Whys Analysis
Figure 20 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Treatment Type, 2021 Vs 2030, %
Figure 21 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Replacement Therapy, 2021 Vs 2030, %
Figure 22 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Route of Drug Administration, 2021 Vs 2030, %
Figure 23 Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Healthcare Settings, 2021 Vs 2030, %
Figure 24 U.S. Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 25 Canada Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 26 Rest of North America Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 27 UK Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 28 Germany Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 29 Spain Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 30 Italy Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 31 France Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 32 Rest of Europe Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 33 China Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 34 Japan Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 35 India Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 36 Australia Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 37 South Korea Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 38 Rest of Asia Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 39 Brazil Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 40 Mexico Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 41 Rest of Latin America Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 42 GCC Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 43 Africa Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
Figure 44 Rest of Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market (US$ Million), 2020-2030
List of Tables
Table 1 Global Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 2 Global Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 3 Global Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 4 Global Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 5 North America Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 6 North America Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 7 North America Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 8 North America Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 9 U.S. Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 10 U.S. Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 11 U.S. Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 12 U.S. Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 13 Canada Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 14 Canada Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 15 Canada Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 16 Canada Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 17 Rest of North America Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 18 Rest of North America Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 19 Rest of North America Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 20 Rest of North America Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 21 UK and European Union Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 22 UK and European Union Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 23 UK and European Union Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 24 UK and European Union Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 25 UK Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 26 UK Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 27 UK Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 28 UK Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 29 Germany Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 30 Germany Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 31 Germany Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 32 Germany Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 33 Spain Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 34 Spain Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 35 Spain Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 36 Spain Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 37 Italy Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 38 Italy Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 39 Italy Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 40 Italy Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 41 France Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 42 France Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 43 France Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 44 France Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 45 Rest of Europe Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 46 Rest of Europe Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 47 Rest of Europe Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 48 Rest of Europe Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 49 Asia Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 50 Asia Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 51 Asia Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 52 Asia Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 53 China Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 54 China Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 55 China Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 56 China Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 57 Japan Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 58 Japan Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 59 Japan Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 60 Japan Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 61 India Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 62 India Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 63 India Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 64 India Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 65 Australia Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 66 Australia Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 67 Australia Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 68 Australia Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 69 South Korea Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 70 South Korea Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 71 South Korea Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 72 South Korea Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 73 Latin America Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 74 Latin America Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 75 Latin America Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 76 Latin America Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 77 Brazil Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 78 Brazil Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 79 Brazil Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 80 Brazil Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 81 Mexico Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 82 Mexico Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 83 Mexico Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 84 Mexico Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 85 Rest of Latin America Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 86 Rest of Latin America Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 87 Rest of Latin America Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 88 Rest of Latin America Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 89 Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 90 Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 91 Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 92 Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 93 GCC Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 94 GCC Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 95 GCC Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 96 GCC Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 97 Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 98 Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 99 Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 100 Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)
Table 101 Rest of Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Treatment Type, 2020-2030, USD (Million)
Table 102 Rest of Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Replacement Therapy, 2020-2030, USD (Million)
Table 103 Rest of Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Route of Drug Administration, 2020-2030, USD (Million)
Table 104 Rest of Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market By Healthcare Settings, 2020-2030, USD (Million)

Companies Mentioned

  • Baxter Healthcare Corporation
  • Biogen
  • Pfizer
  • F. Hoffman La Roche
  • Sanofi
  • Ferring Pharmaceuticals
  • Genentech Inc.
  • Bristol Myers Squibb
  • Novo Nordisk
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical
  • CSL Behring
  • Bayer AG

Related Topics

Related Reports

Von Willebrand Disease Treatment Market by Disease Type, Treatment, Route of Administration - Global Forecast 2025-2030 - Product Image

Von Willebrand Disease Treatment Market by Disease Type, Treatment, Route of Administration - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Von Willebrand Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Von Willebrand Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 128 Pages
  • Global
From
Von Willebrand's Disease - Pipeline Insight, 2024 - Product Image

Von Willebrand's Disease - Pipeline Insight, 2024

  • Clinical Trials
  • 40 Pages
  • Global
From
Von Willebrand Disease. Basic and Clinical Aspects. Edition No. 1 - Product Image

Von Willebrand Disease. Basic and Clinical Aspects. Edition No. 1

  • Book
  • 268 Pages
Textbook of Von Willebrand Disease. Basic and Clinical Aspects. Edition No. 2 - Product Image

Textbook of Von Willebrand Disease. Basic and Clinical Aspects. Edition No. 2

  • Book
  • 304 Pages
Copyright © 2002-2024 Research and Markets. All Rights Reserved.